Integra LifeSciences (IART)
Builds neurosurgery, ENT, surgical-instrument and regenerative tissue products.
Something off on this page? Send us feedback.
Sells medical technologies through Codman Specialty Surgical and Tissue Technologies, spanning neurosurgery, ENT, specialty instruments, wound reconstruction and private-label regenerative products. The larger Codman franchise carries the portfolio, while medical-device quality systems, supply reliability and remediation execution shape operations.
Operates through Codman Specialty Surgical and Tissue Technologies. Codman covers neurosurgery, neuro-critical care, ENT and specialty instruments, with brands such as CUSA, DuraGen, DuraSeal, Mayfield, Bactiseal and Acclarent; Tissue Technologies covers wound reconstruction, care and private-label regenerative products.
Built from a collagen technology origin, the portfolio expanded through Jarit, Codman, ACell, SIA/DuraSorb and Acclarent. Codman anchors the larger surgical side and expanded the company's global neurosurgery position, while ACell and DuraSorb deepened wound and soft-tissue reconstruction.
Operations depend on regulated medical-device quality systems, supply reliability and remediation execution after FDA warning letters and recalls tied to Boston, Mansfield and Plainsboro facilities.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 28, 2026 | UBS | Initiate | Rating: —Target: — | Target: $19 |
| Jul 16, 2026 | Truist Financial | Target | Target: $12 | Target: $19 |
| Jul 8, 2026 | BMO Capital | Initiate | Rating: —Target: — | Target: $19 |
| Jun 18, 2026 | Argus Research | Target | Target: — | Target: $25 |
| May 28, 2026 | Citigroup | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $274.1M · Total debt $2.04B · Total assets $3.59B · Shareholders' equity $1.05B
- Revenue
- $418.8M
- Operating income
- $19.3M
- Net income
- $4.5M
No dividends on record.
| Institutions | 96.06% | 74.71M shares | |
|---|---|---|---|
| 213 holders · as of Jun 30, 2026 | |||
| Insiders | 16.97% | 13.20M shares | |
| 16 holders · as of Sep 4, 2026 | |||
| Strategic holders | 2.51% | 1.96M shares | |
| 1 holder · as of Aug 12, 2019 | |||
| Adds to | 115.54% | ||
77.77M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 115.54%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Richard E. Caruso, Ph.D.Insider | 14.21% | 11.05M | filed Feb 11, 2020 |
BlackRock, Inc.Institution | 13.74% | 10.68M | as of Jun 30, 2026 |
Capital Research Global InvestorsInstitution | 11.73% | 9.12M | filed Feb 14, 2020 |
Rubric Capital Management LPInstitution | 9.97% | 7.75M | as of Jun 30, 2026 |
Invesco Ltd.Institution | 4.82% | 3.75M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 5, 2025 | Jeffrey A. Graves | director | +9,000 | $11.35 |
- Medtronic
Broad neurosurgery and ENT device rival across hospital workflows
- Stryker
Neurotechnology and surgical-instrument rival in cranial procedures
- Smith & Nephew (ADR)
Advanced wound, sports-medicine, and ENT rival
- STERIS
Specialty surgical-instrument rival in OR and procedure suites
- Organogenesis
Regenerative wound-care rival with collagen and placental matrices
- MiMedx
Advanced wound and placental-allograft rival
- Axogen
Peripheral nerve-repair rival focused on allografts and conduits
- BD
Surgical mesh and biologic-graft rival in soft-tissue repair
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Integra LifeSciences | $15.96 | +2.37% | $1.21B | — | 6.3 | 0.7 | +0.8% |
| Medtronic | $90.94 | −0.88% | $117.44B | 22.6 | 15.2 | 3.1 | +13.7% |
| Stryker | $275.55 | +0.50% | $105.11B | 28.4 | 17.2 | 4.1 | +9.4% |
| Smith & Nephew (ADR) | $27.48 | −0.76% | $11.63B | 19.0 | — | 1.8 | +4.6% |
| STERIS | $208.53 | +0.75% | $20.17B | 25.3 | 18.2 | 3.3 | +7.1% |
| Organogenesis | $1.48 | +5.36% | $180.1M | — | — | 0.4 | −56.7% |
| MiMedx | $4.91 | +1.98% | $701.1M | 120.2 | 49.4 | 2.0 | −34.7% |
| Axogen | $44.85 | −2.36% | $2.47B | — | 75.8 | 9.8 | +23.1% |
| BD | $182.91 | +1.22% | $49.79B | 54.4 | 13.8 | 2.4 | −9.6% |
| Median | 26.9 | 17.7 | 2.8 | +5.9% |